Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Capricor Therapeutics (CAPR) stocks in Canada

Learn how to easily invest in Capricor Therapeutics stocks.

Capricor Therapeutics is a biotechnology business based in the US. Capricor Therapeutics stocks (CAPR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.07 – a decrease of 5.33% over the previous week. Capricor Therapeutics employs 26 staff and has a trailing 12-month revenue of around $302,728.

How to buy shares in Capricor Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CAPR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Capricor Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Capricor Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Capricor Therapeutics's stock price has had significant positive movement.

Its last market close was $3.02, which is 53.97% up on its pre-crash value of $1.39 and 243.18% up on the lowest point reached during the March crash when the stocks fell as low as $0.88.

If you had bought $1,000 worth of Capricor Therapeutics stocks at the start of February 2020, those stocks would have been worth $773.34 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,013.34.

Capricor Therapeutics stock price (NASDAQ:CAPR)

Use our graph to track the performance of CAPR stocks over time.

Capricor Therapeutics shares at a glance

Information last updated 2022-01-15.
Latest market close$3.02
52-week range$2.75 - $8.40
50-day moving average $3.24
200-day moving average $4.04
Wall St. target price$13.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.82

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Capricor Therapeutics price performance over time

Historical closes compared with the close of $3.02 from 2022-01-18

1 week (2022-01-12) -5.33%
1 month (2021-12-17) -8.21%
3 months (2021-10-19) -23.74%
6 months (2021-07-19) -33.77%
1 year (2021-01-19) -44.49%
2 years (2020-01-17) 65.03%
3 years (2019-01-18) 354.14%
5 years (2017-01-19) 23.64%

Capricor Therapeutics financials

Revenue TTM $302,728
Gross profit TTM $-8,146,750
Return on assets TTM -29.54%
Return on equity TTM -53.65%
Profit margin 0%
Book value $1.52
Market capitalisation $74.6 million

TTM: trailing 12 months

Capricor Therapeutics share dividends

We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.

Have Capricor Therapeutics's shares ever split?

Capricor Therapeutics's shares were split on a 1:10 basis on 5 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.

Capricor Therapeutics share price volatility

Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $2.75 up to $8.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 6.1637. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Capricor Therapeutics overview

Capricor Therapeutics, Inc. , a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Stocks similar to Capricor Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site